Robert J. Spiegel
PTC Therapeutics (United States)(US)
Publications by Year
Research Areas
Muscle Physiology and Disorders, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Biotin and Related Studies, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial(2017)451 cited
- → Ataluren treatment of patients with nonsense mutation dystrophinopathy(2014)426 cited
- → The 6‐minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study(2013)349 cited
- → Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial(2014)334 cited
- → THE 6‐minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study(2013)297 cited
- → An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults(1984)251 cited
- → Direct access to serum macromolecules by intraerythrocytic malaria parasites(1991)219 cited
- → Renal and Metabolic Complications of Undifferentiated and Lymphoblastic Lymphomas(1981)168 cited
- → Combined recombinant human interferon alpha2 and cytotoxic agents studied in a clonogenic assay(1985)133 cited
- → Plasma lipid alterations in leukemia and lymphoma(1982)131 cited